IGC
IGC Pharma, Inc. AMEX Listed May 24, 2006$0.26
+0.42%
vs $0.26
Mkt Cap $20.1M
52w Low $0.25
6.6% of range
52w High $0.47
50d MA $0.30
200d MA $0.32
P/E (TTM)
—
EV/EBITDA
—
P/B
3.2x
Debt/Equity
0.0x
ROE
-89.3%
P/FCF
-3.8x
RSI (14)
31.40
ATR (14)
$0.01
Beta
0.31
50d MA
$0.30
200d MA
$0.32
Avg Volume
694.3K
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
10224 Falls Road · Potomac, MD 20854 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | AMC | -0.02 | -0.02 | +0.0% | — | — | — | — | — | — | — | — |
| Apr 3, 2026 | AMC | -0.02 | -0.02 | +0.0% | — | — | — | — | — | — | — | — |
| Nov 14, 2025 | AMC | -0.02 | -0.02 | +0.0% | 0.36 | +2.1% | -5.0% | -1.5% | -2.7% | -4.2% | +0.9% | — |
| Aug 19, 2025 | AMC | -0.03 | -0.02 | +20.0% | 0.37 | -0.9% | -3.4% | -2.1% | +3.8% | +2.3% | +4.4% | — |
| Aug 14, 2025 | AMC | -0.03 | -0.02 | +33.3% | 0.36 | +2.8% | +2.8% | +2.8% | -2.3% | -3.4% | -2.1% | — |
| Jun 30, 2025 | AMC | -0.02 | -0.02 | +0.0% | 0.31 | +2.2% | -0.8% | +1.2% | -1.5% | +4.9% | +0.1% | — |
| Jun 27, 2025 | AMC | -0.02 | -0.01 | +50.0% | 0.31 | +0.6% | -1.0% | -0.8% | +1.2% | -1.5% | +4.9% | — |
| Feb 18, 2025 | AMC | -0.03 | -0.02 | +33.3% | 0.31 | -1.3% | -3.7% | +0.9% | -0.1% | -3.9% | +0.4% | — |
| Feb 14, 2025 | AMC | -0.03 | -0.02 | +33.3% | 0.31 | -0.5% | -2.1% | -3.7% | +0.9% | -0.1% | -3.9% | — |
| Nov 14, 2024 | AMC | -0.03 | -0.02 | +33.3% | 0.36 | -1.9% | -5.2% | +3.5% | -2.3% | -2.9% | +5.8% | — |
| Nov 12, 2024 | AMC | -0.02 | -0.02 | -22.8% | 0.38 | -5.3% | -3.6% | -2.6% | -5.2% | +3.5% | -2.3% | — |
| Aug 8, 2024 | AMC | -0.03 | -0.03 | -15.8% | 0.39 | +4.8% | +4.6% | -0.0% | +0.0% | +4.4% | -0.5% | — |
| Jun 24, 2024 | AMC | -0.00 | -0.04 | -900.0% | 0.47 | -6.3% | -8.1% | -2.4% | +1.0% | +2.1% | +1.2% | — |
| Feb 14, 2024 | AMC | -0.04 | -0.09 | -125.0% | 0.30 | +3.0% | +0.1% | +1.2% | -2.7% | -3.7% | -3.9% | — |
| Nov 9, 2023 | AMC | — | -0.05 | — | 0.30 | +2.2% | -2.0% | +4.1% | -0.3% | -1.0% | +1.1% | — |
| Jul 7, 2023 | AMC | — | -0.08 | — | 0.41 | -1.3% | -6.6% | +4.4% | -5.0% | +2.6% | -6.2% | — |
| Jun 30, 2023 | AMC | — | -0.13 | — | 0.31 | +2.7% | +4.2% | +4.7% | -1.7% | +22.7% | -6.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.27 | $0.28 | +3.1% | +3.5% | +7.5% | +0.3% | -1.6% | +4.4% |
| Feb 23 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.26 | $0.28 | +7.6% | +2.2% | +4.8% | +4.0% | -1.8% | -2.6% |
| Dec 9 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.29 | $0.29 | -0.4% | +2.5% | +14.8% | -4.1% | +6.0% | -3.9% |
| Aug 26 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.37 | $0.38 | +0.8% | +4.4% | +15.7% | -5.9% | +1.4% | +3.2% |
| Mar 6 | Alliance Global Partners | Maintains | Buy → Buy | — | $0.28 | $0.27 | -3.5% | +8.8% | +0.6% | +6.5% | -4.1% | +9.6% |
| Feb 24 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.30 | $0.30 | -0.2% | -3.9% | +0.4% | -0.6% | -0.7% | +2.8% |
| Dec 5 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.36 | $0.36 | -0.6% | +0.4% | +2.3% | -1.4% | +2.2% | +3.5% |
| Sep 3 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.36 | $0.36 | -0.0% | -3.1% | -1.0% | +0.0% | +2.3% | +5.0% |
| Jul 29 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.45 | $0.46 | +2.4% | +0.9% | -2.4% | +3.2% | +0.8% | -6.1% |
| Jun 21 | Ascendiant Capital | Maintains | Buy → Buy | — | $0.40 | $0.42 | +3.8% | +36.6% | -14.7% | -8.1% | -2.4% | +1.0% |
No insider trades available.
8-K · 1.01
! Medium
IGC Pharma, Inc. -- 8-K 1.01: Financing / Debt Agreement
IGC Pharma secured financing through a Securities Purchase Agreement, providing capital to support operations and strategic initiatives, though specific terms and amount require review of full filing details.
Apr 20
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
IGC Pharma's strategic media partnership aims to boost investor visibility and potentially increase stock demand among institutional and retail investors through coordinated national television and digital distribution.
Mar 30
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
IGC secured new debt financing through One Deck Capital and Vanquish Funding, potentially providing liquidity for operations or growth, though investors should scrutinize terms and dilution risk.
Mar 12
Institutional (13F) — Top 18
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 718,436 | $189K | New | Mar 2026 |
| 2 | Renaissance Technologies Llc | 483,975 | $127K | Reduced | Mar 2026 |
| 3 | Susquehanna International Group, Llp | 122,595 | $32K | Reduced | Mar 2026 |
| 4 | Northern Trust Corp | 113,407 | $30K | — | Mar 2026 |
| 5 | Lawood & Co | 75,000 | $20K | — | Mar 2026 |
| 6 | Dearborn Partners Llc | 59,401 | $16K | Reduced | Mar 2026 |
| 7 | Truist Financial Corp | 36,667 | $10K | — | Dec 2025 |
| 8 | Morgan Stanley | 35,414 | $10K | — | Dec 2025 |
| 9 | Commonwealth Equity Services, Llc | 33,348 | $9K | Reduced | Dec 2025 |
| 10 | Wealthcare Advisory Partners Llc | 10,000 | $3K | New | Mar 2026 |
| 11 | Schneider Downs Wealth Management Advisors, Lp | 10,000 | $3K | New | Mar 2026 |
| 12 | Ubs Group Ag | 8,097 | $2K | Reduced | Mar 2026 |
| 13 | Trask Adam Roland | 5,000 | $1K | New | Mar 2026 |
| 14 | Geneos Wealth Management Inc. | 3,000 | $780 | — | Mar 2026 |
| 15 | Cwm, Llc | 1,000 | $263 | New | Mar 2026 |
| 16 | Farther Finance Advisors, Llc | 101 | $27 | Added | Mar 2026 |
| 17 | Dhjj Financial Advisors, Ltd. | 80 | $22 | — | Mar 2026 |
| 18 | Virtu Financial Llc | 23,233 | $6 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 455,489 | $126K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 98,554 | $27K | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 95,369 | $26K | Feb 2026 |
Valuation
Market Cap
$20.1M
Enterprise Value
$19.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.05x
P/B
3.18x
P/S
16.97x
P/FCF
-3.81x
EV/EBITDA
—
Shares Out
76.5M
Financials (TTM)
Revenue
$1.2M
Net Income
-$6.5M
EBITDA
-$6.2M
Free Cash Flow
-$5.3M
Op Cash Flow
-$4.8M
EPS Basic
$-0.09
EPS Diluted
$-0.07
EPS Forward
$-0.09
Gross Margin
29.7%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$8.7M
Total Liab.
$2.4M
Total Equity
$6.3M
Cash
$405K
LT Debt
$134K
Book Value/Sh
$0.08
Debt/Equity
0.04x
Current Ratio
1.28
Quick Ratio
0.68
Returns & Growth
ROE
-89.3%
ROA
-74.2%
ROIC
-113.1%
Rev Growth YoY
-5.5%
EPS Growth YoY
+57.7%
Price Returns
2W
-3.4%
1M
-9.6%
3M
+4.2%
6M
-9.5%
12M
-8.1%
Technicals
52W High
$0.47
52W Low
$0.25
50d MA
$0.30
200d MA
$0.32
RSI (14)
31.40
ATR (14)
$0.01
Beta
0.31
Avg Volume
694K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 3:06pm
· Source: financialmodelingprep.com